In the section "Monday June 6, 8:00 a.m. to noon CT., Hall A" the Abstract No. should be 3053 (sted 4023).
The corrected release reads:
RESPONSE GENETICS ANNOUNCES PRESENTATION OF LUNG CANCER AND ESOPHAGEAL CANCER STUDY RESULTS AT 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
New Data Support Use of Cancer Biomarkers for Patient Screening and Treatment SelectionResponse Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3 to June 7, 2011. Study results are based in part on the company’s proprietary technology and approach. Data will highlight clinical results in non-small cell lung cancer (NSCLC) and esophageal cancer and approaches to improve cancer care. “The results to be presented at ASCO 2011 are the product of Response Genetics’ commitment to finding new ways to help patients and to personalize cancer care,” said Kathleen Danenberg, CEO of Response Genetics. “Through scientific and clinical collaborations we are applying our powerful technology to identify lung cancer patients likely to benefit from new and existing therapies and to investigate the use of predictive and prognostic markers in the treatment of esophageal cancers.” All studies presented used technology developed by Response Genetics to isolate RNA from formalin-fixed, paraffin-embedded (FFPE) archived tissue for quantitative RT-PCR analysis of gene expression. Following is a summary of presentations: Poster Discussion Sections Saturday June 4, 5:00 p.m. to 6:00 p.m. CT., S 100bc Abstract No. 10520: Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. A panel of single and multiplexed RT-PCR assays capable of detecting all nine known EML4-ALK fusion gene transcripts and ALK RNA level variants was used to identify ALK-positive patients and to investigate the impact of crizotinib on tumor sensitivity to chemotherapy. Of the 1,889 NSCLC specimens tested, 75 (4.0 percent) were EML4-ALK positive – all were adenocarcinomas and none harbored EGFR or K-Ras mutations. This unique approach allows the rapid, large-scale screening of NSCLC tissues for ALK fusion gene transcripts.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV